Tyra Biosciences (NASDAQ:TYRA) Coverage Initiated at UBS Group

UBS Group assumed coverage on shares of Tyra Biosciences (NASDAQ:TYRA - Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $28.00 price objective on the stock.

A number of other equities research analysts have also weighed in on the company. Oppenheimer boosted their price target on Tyra Biosciences from $25.00 to $33.00 and gave the stock an "outperform" rating in a research note on Thursday, September 19th. HC Wainwright cut their target price on Tyra Biosciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Monday, November 11th. Wedbush reiterated an "outperform" rating and set a $28.00 price target on shares of Tyra Biosciences in a research note on Friday, October 25th. Finally, Bank of America upgraded Tyra Biosciences from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $30.50.

Tyra Biosciences Stock Down 0.7 %

Shares of NASDAQ TYRA traded down $0.11 during mid-day trading on Tuesday, reaching $15.95. 368,741 shares of the company were exchanged, compared to its average volume of 237,185. Tyra Biosciences has a 1 year low of $11.32 and a 1 year high of $29.60. The firm has a 50-day moving average of $15.48 and a 200 day moving average of $19.24. The stock has a market cap of $807.12 million, a price-to-earnings ratio of -9.91 and a beta of 1.04.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). On average, equities analysts forecast that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In other news, CFO Alan Fuhrman acquired 9,500 shares of the firm's stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $152,000.00. Following the completion of the transaction, the chief financial officer now owns 12,849 shares in the company, valued at approximately $205,584. The trade was a 283.67 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Todd Harris sold 10,035 shares of the firm's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $24.31, for a total value of $243,950.85. Following the sale, the chief executive officer now owns 1,467,338 shares in the company, valued at $35,670,986.78. This trade represents a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 84,160 shares of company stock worth $1,827,047 over the last quarter. 15.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tyra Biosciences

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its stake in shares of Tyra Biosciences by 1.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock worth $8,667,000 after buying an additional 3,896 shares during the period. Franklin Resources Inc. purchased a new stake in Tyra Biosciences in the 3rd quarter worth $278,000. Barclays PLC raised its position in Tyra Biosciences by 200.5% during the third quarter. Barclays PLC now owns 37,625 shares of the company's stock worth $884,000 after acquiring an additional 25,106 shares during the period. State Street Corp lifted its holdings in Tyra Biosciences by 4.4% during the third quarter. State Street Corp now owns 384,732 shares of the company's stock valued at $9,045,000 after purchasing an additional 16,248 shares in the last quarter. Finally, Polar Asset Management Partners Inc. acquired a new stake in shares of Tyra Biosciences in the third quarter valued at about $2,071,000. Institutional investors and hedge funds own 84.14% of the company's stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.